SCENESSE® DNA REPAIR STUDY IN HEALTHY VOLUNTEERS APPROVED
Melbourne, Australia, 30 November 2020 CLINUVEL PHARMACEUTICALS LTD today announced that it...
Read MoreJefferies Virtual London Healthcare Conference Presentation
20 November 2020 Download presentation & speaker’s notes
Read MoreChair's Letter To Shareholders
19 November 2020 Dear fellow shareholder, I look back at a year...
Read MoreResults of Annual General Meeting
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations...
Read MoreMANAGING DIRECTOR’S PRESENTATION TO CLINUVEL ANNUAL GENERAL MEETING
The following is a transcript of the Managing Director’s presentation to the...
Read MoreCHAIR’S ADDRESS TO CLINUVEL ANNUAL GENERAL MEETING
I am up for re-election today, thank you for those who supported...
Read MoreCLINUVEL Strategic Update – Executive Summary
CLINUVEL PHARMACEUTICALS LTD today released a strategic update on its business. An...
Read MoreFurther Research Coverage Initiated on CLINUVEL
CLINUVEL PHARMACEUTICALS LTD today informed its shareholders and interested investors that Jefferies...
Read MoreCLINUVEL Annual General Meeting 2020
CLINUVEL PHARMACEUTICALS LTD’s 2020 Annual General Meeting (AGM) will be held on...
Read MoreSCIENTIFIC COMMUNIQUÉ VI
Ultraviolet Radiation Damage and Oxidative Stress in Skin Cancer. October 2020 Introduction...
Read MoreCLINUVEL News & Facts site live
Earlier this week CLINUVEL launched a new microsite, CLINUVEL News & Facts. The CLINUVEL...
Read MoreKommuniqué V, 20-23 September 2020
Liebe Aktionäre, Freunde, Während die Welt darum kämpft, die Verbreitung von...
Read MoreCLINUVEL Newsletter V
Dear shareholders, friends, As the world battles on to control the...
Read More